AI and the Pharmaceutical Industry — 2026-11-07 (Sat)

Overview

The most significant development in pharma AI investment today is the partnership between Roche and Chai Discovery. Roche signaled that it intends to apply AI-driven drug discovery models across its entire pipeline rather than to individual projects. In a similar move, UCB teamed up with Cradle on antibody discovery. Large pharmaceutical companies continue to partner with external AI specialists.

By Category

In drug discovery, the deals include a funding round for Venomics AI, an investment by Kos Biotechnology Partners in Fathom Therapeutics, and iSpecimen's acquisition of Foldlab's AI products. Targets range from companies using animal venom as source material to platform-type businesses to expansion through acquisition, so investment is becoming more fragmented. Even within this trend, the Roche–Chai Discovery partnership stands out as a deal led by a major pharmaceutical company.

In company-wide AI infrastructure and governance, Veeva Systems was selected as the core CRM for a large biopharma company's AI rollout. AI adoption is reaching beyond drug discovery into the infrastructure for sales and customer management. In Japan, NTT, NTT Docomo Business, and Igaku-Shoin have begun a joint demonstration project with Ubie on a medical AI information platform.

Reading the Investment Map

The only confirmed amount is Venomics AI's $2.7 Mn raise. The amount is small, which suggests that funding is flowing to early-stage AI drug discovery companies. No amounts were disclosed for Kos Biotechnology Partners' investment in Fathom Therapeutics or for iSpecimen's acquisition of Foldlab's AI products. The amounts for the Roche–Chai Discovery and UCB–Cradle partnerships are also unknown. Capital is split between two destinations: startups with AI drug discovery platforms, and partnerships with large pharmaceutical companies.

What to Watch

Whether the target programs and contract terms of the Roche–Chai Discovery partnership will be disclosed. 2. The details of the UCB–Cradle antibody discovery partnership, and whether other major pharmaceutical companies move toward similar external AI partnerships.